LON:BPCR BioPharma Credit (BPCR) Share Price, News & Analysis → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Free BPCR Stock Alerts GBX 0.88 0.00 (0.00%) (As of 05:21 PM ET) Add Compare Share Share Today's Range 0.87▼ 0.8850-Day Range 0.87▼ 0.9352-Week Range 0.81▼ 0.97Volume2.40 million shsAverage Volume1.86 million shsMarket Capitalization£11.39 millionP/E Ratio6.74Dividend Yield799.09%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendHeadlinesInsider TradesStock AnalysisChartCompetitorsDividendHeadlinesInsider Trades Get BioPharma Credit alerts: Email Address Ad Behind the MarketsTiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> About BioPharma Credit Stock (LON:BPCR)BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in London, the United Kingdom.Read More BPCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPCR Stock News HeadlinesMarch 28, 2024 | insidertrades.comSapna Shah Acquires 20,000 Shares of BioPharma Credit (LON:BPCR) StockFebruary 26, 2024 | nz.finance.yahoo.comBioPharma Credit PLC (BPCP.L)April 19, 2024 | Behind the Markets (Ad)Tiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.February 22, 2024 | finance.yahoo.comInvestors in BioPharma Credit (LON:BPCR) have seen notable returns of 40% over the past five yearsFebruary 7, 2024 | realmoney.thestreet.comBiopharma Credit just downgraded at Jefferies, here's whyJanuary 9, 2024 | markets.businessinsider.comAssessing Ambrx Biopharma: Insights From 7 Financial AnalystsJanuary 8, 2024 | finance.yahoo.comBioPharma Credit Ord (BPCR.L)January 2, 2024 | lse.co.ukBioPharma Credit to fund LumiraDx ahead of acquisition by RocheApril 19, 2024 | Behind the Markets (Ad)Tiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.December 3, 2023 | finance.yahoo.comBioPharma Credit PLC (LON:BPCR) Looks Interesting, And It's About To Pay A DividendOctober 4, 2023 | msn.comTruist Securities Downgrades POINT Biopharma Global (PNT)September 19, 2023 | lse.co.ukBioPharma Credit notes liquidity amendments to LumiraDX loan dealSeptember 12, 2023 | benzinga.comConnect Biopharma Reports First Half 2023 Financial Results and Provides Business UpdateAugust 27, 2023 | finance.yahoo.comInvesting in BioPharma Credit (LON:BPCR) five years ago would have delivered you a 19% gainAugust 24, 2023 | finanznachrichten.deLumiraDx Inc: LumiraDx Reports Second Quarter 2023 ResultsAugust 16, 2023 | forbes.comBest Credit Cards For Recent College Graduates In August 2023August 2, 2023 | marketwatch.comABVC Biopharma Shares Drop 15% After Big Rise TuesdayJuly 25, 2023 | msn.comCantor Fitzgerald Maintains Reata Pharmaceuticals Inc - (RETA) Overweight RecommendationJuly 23, 2023 | forbes.comBest Mobile Credit Card Readers Of 2023July 6, 2023 | msn.comTD Cowen Initiates Coverage of Reata Pharmaceuticals Inc - (RETA) with Outperform RecommendationJune 26, 2023 | msn.comDRI Healthcare Trust says CTI BioPharma repaid $54.8M debtJune 21, 2023 | cnbc.comThis stock could become a 'one-stop shop' for biopharma and rally more than 35%, RBC saysMay 3, 2023 | msn.comHear how Cambrian BioPharma is reinventing drug (and drug company) developmentApril 23, 2023 | finance.yahoo.comBioPharma Credit PLC (LON:BPCR) Passed Our Checks, And It's About To Pay A US$0.018 DividendMarch 20, 2023 | finance.yahoo.comBioPharma Credit's (LON:BPCR) investors will be pleased with their notable 42% return over the last three yearsMarch 13, 2023 | marketwatch.comAmbrx Biopharma Shares Rise 7% After Completing ATM ProgramFebruary 19, 2023 | msn.comThe next big wave of patent cliffs is ahead; expect biopharma M&A to rise – reportSee More Headlines Receive BPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPharma Credit and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 3/15 Dividend2/15/2024Dividend Payable3/15/2024Ex-Dividend for 4/30 Dividend3/28/2024Today4/19/2024Dividend Payable4/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorFinancial Services Industry Asset Management Sub-IndustryN/A Current SymbolLON:BPCR CUSIPN/A CIKN/A Webwww.bpcruk.com Phone44 13 9247 7500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX 0.13 Trailing P/E Ratio6.74 Forward P/E RatioN/A P/E GrowthN/ANet Income£185.07 million Net Margins83.84% Pretax MarginN/A Return on Equity13.65% Return on Assets8.50% Debt Debt-to-Equity RatioN/A Current Ratio21.75 Quick Ratio14.07 Sales & Book Value Annual Sales£220.74 million Price / Sales0.05 Cash FlowGBX 0.73 per share Price / Cash Flow1.19 Book ValueGBX 102 per share Price / Book0.01Miscellaneous Outstanding Shares1,300,000,000Free FloatN/AMarket Cap£11.39 million OptionableNot Optionable Beta0.21 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Pedro Gonzalez de CosioInvestment ManagerMr. Pablo Gerardo Legorreta (Age 59)Investment Manager Mr. Martin G. Friedman (Age 58)Investment Manager Key CompetitorsThames Ventures VCT 2 Healthcare ShsLON:TV2HHonye Financial ServicesLON:HOYEKelso GroupLON:KLSOKRM22LON:KRMAdamsLON:ADAView All CompetitorsInsidersSapna ShahBought 20,000 shares on 3/27/2024Total: £1.44 M ($72.00/share)View All Insider Transactions BPCR Stock Analysis - Frequently Asked Questions How have BPCR shares performed in 2024? BioPharma Credit's stock was trading at GBX 0.84 at the start of the year. Since then, BPCR stock has increased by 4.3% and is now trading at GBX 0.88. View the best growth stocks for 2024 here. How often does BioPharma Credit pay dividends? What is the dividend yield for BioPharma Credit? BioPharma Credit declared a dividend on Thursday, March 21st. Investors of record on Thursday, March 28th will be given a dividend of GBX 0.02 per share on Tuesday, April 30th. This represents a yield of 1.97%. The ex-dividend date of this dividend is Thursday, March 28th. The official announcement can be viewed at this link. Read our dividend analysis for BPCR. Is BioPharma Credit a good dividend stock? BioPharma Credit (LON:BPCR) pays an annual dividend of GBX 7 per share and currently has a dividend yield of 8.47%. BPCR has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 5,384.62%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for BPCR. What other stocks do shareholders of BioPharma Credit own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioPharma Credit investors own include AFPO.L (AFPO), Altius Minerals (ATUSF), LiDCO Group Plc (LID.L) (LID), 21512 (SAT.L) (SAT), San Juan Basin Royalty Trust (SJT), ANGLE (AGL), Hochschild Mining (HOC), SPX FLOW (FLOW), Fulcrum Utility Services (FCRM) and DX (Group) (DX). How do I buy shares of BioPharma Credit? Shares of BPCR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:BPCR) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIYour Money is Not SafeAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.